Co-Mepril

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-Mepril

Quick Facts

Property Description
Active Ingredients ACE Inhibitor + Thiazide Diuretic (Fixed-Dose Combination)
Form Oral Tablet
Pharmacological Class Antihypertensive Agent
Common Use Managing high blood pressure (Essential Hypertension)
Origin Synthetic Chemical Compound

What Type of Medicine is Co-Mepril? (Pharmacological Class and Identity)

Co-Mepril is a fixed-dose combination medication utilized for the management of high blood pressure. It is a synthetic drug supplied as an oral tablet that combines two distinct cardiovascular medicines: an Angiotensin-Converting Enzyme (ACE) inhibitor and a thiazide diuretic. Its formulation is intended for individuals who require both classes of medication to manage their blood pressure levels.

This combination product is classified as an antihypertensive agent and is typically available by prescription only (Rx). The use of this dual-component strategy is a recognized clinical approach for reaching target blood pressure levels.


Co-Mepril’s Active Ingredients and Composition

Co-Mepril is defined by its two main components, which represent its International Nonproprietary Name (INN) combination. One component is an ACE inhibitor (such as enalapril or lisinopril) and the other is a diuretic (such as hydrochlorothiazide). The presence of two different agents allows for a dual action against hypertension.

This fixed-dose composition differs from single-agent treatments by addressing the condition via two separate, complementary pathways simultaneously. This approach is designed to potentially improve patient adherence to therapy compared to the administration of two separate medications.


General Therapeutic Purpose

The primary general therapeutic purpose of Co-Mepril is the long-term treatment of essential hypertension (chronic high blood pressure). Its use is typically indicated for adults whose blood pressure remains uncontrolled despite previous monotherapy. By consistently lowering systemic blood pressure, the medication reduces the overall workload on the cardiovascular system and is intended to minimize the risk of serious cardiovascular events.

Regulatory References

  1. Fixed-Dose Combination Antihypertensive Therapy (ACE Inhibitor/Diuretic)

What side effects are possible with Co-Mepril?

Possible Side Effects and Safety Information

The safety profile of Co-Mepril, a fixed-dose combination of an ACE inhibitor and a thiazide diuretic, is characterized by adverse reactions documented in official regulatory labeling. These effects are classified by frequency and the body system affected, consistent with government health authority standards.

Frequency and System Classification

Adverse reactions that are frequently documented (Common) include dizziness, headache, fatigue, and a persistent non-productive cough. The combination also commonly causes orthostatic hypotension (low blood pressure upon standing). Effects classified by the systems they involve include:

  • Metabolic/Electrolyte: Changes in blood chemistry such as hypokalemia (low potassium), hyperkalemia (high potassium), and hyperglycemia.
  • Ocular: Rare reports of acute transient myopia and secondary acute angle-closure glaucoma.

Serious Adverse Reactions and Key Restrictions

Regulatory documents highlight several serious adverse reactions. The most significant is Angioedema (swelling of the face, lips, tongue, or throat), which can be life-threatening and is reported to occur more frequently in African-American patients. Additionally, the medicine is subject to a Boxed Warning regarding Fetal Toxicity; use is contraindicated in pregnancy during the second and third trimesters due to risk of injury or death to the fetus.

Time-related patterns note that symptomatic hypotension is most likely at the initiation of therapy. Safety restrictions formally contraindicate use in patients with Anuria, severe renal impairment (creatinine clearance leq 30 mL/min), a history of Angioedema related to any ACE inhibitor, and hypersensitivity to sulfonamide-derived drugs. Cumulative, long-term use of the thiazide component is associated with an increased regulatory risk of Non-melanoma Skin Cancer.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented presentation and required actions for a Co-Mepril overdose, based on government regulatory labeling.

Documented Presentations and Severity:

Overdose may present primarily with Profound Hypotension, a severe drop in blood pressure. Documented clinical signs also include Volume Depletion and significant Electrolyte Imbalance, notably hypokalemia and hyponatremia. Severe exposures are officially classified as potentially life-threatening due to the risk of progression to Circulatory Shock or Acute Renal Failure. Labeling notes that patients with pre-existing renal dysfunction or severe volume depletion are at heightened risk of severe outcomes.

Required Emergency Actions:

Regulatory guidance mandates that Immediate Medical Attention must be sought for any suspected overdose. Emergency services should be contacted if symptoms of severe hypotension, fainting (syncope), or signs of circulatory collapse occur. Official management is defined as symptomatic and supportive treatment, focused on volume expansion through intravenous infusion and careful correction of fluid and electrolyte imbalances. Regulatory documents explicitly state that No specific antidote is known for this combination, necessitating continuous hospital observation and rigorous monitoring of vital signs, serum electrolytes, and renal function.

Therapeutic Uses of Co-Mepril

What Co-Mepril Treats: Main Uses and Benefits

Co-Mepril is used to help manage the symptoms and clinical manifestations of essential hypertension (high blood pressure). This combination medicine is applied as a part of a therapeutic plan for blood pressure management, where control is important for overall health and to support long-term well-being.

Co-Mepril is commonly used to help manage the overall symptom burden associated with elevated blood pressure. It is applied across therapeutic domains where elevated pressure causes systemic physiological strain.

Supporting Symptomatic Comfort

This medication is relevant in clinical settings marked by increased discomfort or tension, providing supportive therapeutic benefit. It helps to moderate distressing symptoms and assists with maintaining a sense of stability during symptomatic episodes. It is often applied when symptoms create noticeable interference with daily functioning.

Quick Fact: Managing Heightened Symptoms
Co-Mepril is commonly used to help manage groups of symptoms that may become intense or disruptive, especially in situations where additional symptomatic support is needed to maintain functional stability.

Regulatory References

  1. MedlinePlus Drug Information on Enalapril and Hydrochlorothiazide

Eligibility and Restrictions for Use

Who Can and Cannot Use Co-Mepril: Official Regulatory Information

Co-Mepril is an approved medicine for use in adults diagnosed with essential hypertension. However, eligibility is strictly defined by regulatory standards, with several absolute exclusions and conditions that limit use.

Contraindicated Populations (Must Not Use)

Category Regulatory Status
Pregnancy Contraindicated in the second and third trimesters. Discontinuation is mandatory upon detection of pregnancy.
Prior Angioedema Contraindicated if a patient has a history of angioedema related to any prior Angiotensin-Converting Enzyme (ACE) inhibitor therapy.
Allergy Contraindicated in patients with a known hypersensitivity to any component of the medicine or to sulfonamide-derived drugs.
Anuria Contraindicated in patients who are anuric (unable to pass urine).

Restricted or Conditional Use

Use is not recommended in the pediatric population as the safety and efficacy of the combination have not been established. Conditional use is required for patients with severe renal impairment (kidney issues) or severe hepatic impairment (liver issues). Furthermore, the medicine is contraindicated in patients with diabetes who are taking the blood pressure drug Aliskiren, and those taking a Sacubitril/Valsartan combination.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Co-Mepril (an ACE Inhibitor + Thiazide Diuretic combination) based on strict prohibitions and documented changes to exposure and systemic effects.

Formal Interaction Restrictions

Classification Interacting Agents Regulatory Statement
Contraindicated Sacubitril/Valsartan Co-administration is prohibited; a 36-hour wash-out period is mandatory when switching to or from Co-Mepril.
Contraindicated Aliskiren Forbidden in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min) due to dual RAS blockade risk.
Risk of Hyperkalemia Potassium Supplements, Potassium-Sparing Diuretics Documented risk of severe hyperkalemia due to additive pharmacodynamic effects.

Pharmacokinetic and Pharmacodynamic Statements

Co-administration with Lithium salts results in reduced renal clearance of Lithium, leading to increased serum concentrations and documented risk of toxicity.

Regulatory warnings note that concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may both diminish the antihypertensive effect and increase the risk of renal function deterioration. Furthermore, the combination of alcohol is documented to exacerbate the hypotensive effects of Co-Mepril.

Pharmacokinetic data indicate that both elderly patients and those with renal impairment (GFR le 30 mL/ min) show higher systemic exposure and prolonged half-life of the active components.

Mechanism of Action

Co-Mepril is a fixed-dose combination product containing enalapril and hydrochlorothiazide, exerting its physiological modulation via two independent molecular pathways.

Enalapril, a prodrug, is hydrolyzed in vivo to its active metabolite, enalaprilat. Enalaprilat functions as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), a peptidyl dipeptidase. ACE is primarily located in the vascular endothelium and catalyzes the conversion of angiotensin I to angiotensin II. By inhibiting ACE, enalaprilat reduces circulating and tissue levels of angiotensin II. This reduction decreases the signaling at the AT1 receptor, leading to diminished direct vasoconstriction and reduced stimulation of aldosterone secretion by the adrenal cortex. The downstream cascade involves a decrease in peripheral arterial resistance and a concurrent reduction in sodium and fluid retention.

Hydrochlorothiazide acts on the kidney, specifically targeting the Sodium-Chloride Cotransporter (NCC) (or SLC12A3) on the apical membrane of the distal convoluted tubule cells. It is an inhibitor of this transport protein, blocking the active reabsorption of sodium ( Na^+) and chloride ( Cl^-) ions from the tubular lumen. The intracellular consequence is an osmotic gradient that retains water in the renal tubule, increasing the excretion of Na^+, Cl^-, and water. This system-level action results in a net decrease in extracellular fluid volume.

Dosage and Administration Information

Instruction Map: How to use Co-Mepril — Administration Guidelines

This map outlines the instructions for the use of Co-Mepril (ACE Inhibitor + Diuretic fixed-dose combination).


Administration Scope

Instruction Detail
Route of administration Oral (swallowed tablet).
Dosing schedule Not for initial therapy; reserved for maintenance in patients whose blood pressure is not controlled by monotherapy. Maximum daily dose is constrained to 20 mg of the ACE inhibitor component and 50 mg of the diuretic component.
Timing in relation to meals Can be taken with or without food.
Preparation requirements The tablet must be swallowed whole; it should not be crushed, split, or chewed.
Age-group administration rules Pediatric (under 18 years): Safety and efficacy are not established. Severe Renal Impairment (CrCl < 30 mL/min): Not recommended.
Missed-dose rules Take the missed dose as soon as remembered, but skip it entirely if it is almost time for the next scheduled dose. Do not double doses.
Special procedural conditions Should be taken at the same time(s) every day to maintain consistent concentration.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral.
Frequency pattern Daily (once or twice per day).
Use-context constraints Must only be used after failure of single-agent therapy for hypertension.

Resulting Procedural Structure

Standard administration sequence:

  • The prescribed fixed-dose combination must be administered orally, typically once per day.
  • The tablet must be swallowed whole to preserve the integrity of the combination formulation.
  • Dosing should occur at a consistent time daily, independent of meal intake.
  • Achievement of the full antihypertensive effect may require continuous treatment for several weeks.

Connection to the Overall Use Protocol

The instructions establish a structured protocol that confirms the medication's primary role as a maintenance therapy for hypertension, defining the limits of its use, such as its specific constraint against use in severe renal impairment. This procedural structure outlines the dosing boundaries and the method of intake to ensure adherence to the established administration method.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Co-Mepril

This section outlines the structure of the clinical research that has evaluated Co-Mepril, a combination drug for high blood pressure. The information summarizes what types of studies have been conducted and what research questions remain uncertain, based on official regulatory and scientific sources.


Evidence for Use in Essential Hypertension

The clinical evaluation of Co-Mepril involved Randomized Controlled Trials (RCTs), a common study design where the fixed-dose combination was evaluated against other treatments or a placebo. These trials typically include adults diagnosed with chronic high blood pressure.

The research evaluated changes measured in Systolic and Diastolic Blood Pressure (BP) associated with the fixed-dose regimen. Studies monitored blood pressure in the clinic setting, and some research included 24-hour ambulatory monitoring to examine how blood pressure evolved over defined time intervals. Findings describe patterns observed in these studies, which often compared the combination product to its individual components used alone.

Studies Evaluating Cardiovascular Outcomes

Extensive research has explored the long-term patterns associated with the drug classes contained in Co-Mepril. This evidence is relevant in research assessing the risk of serious health events linked to long-standing hypertension. Outcomes monitored included the occurrence of serious events such as stroke, myocardial infarction (heart attack), and hospitalization for heart failure. Research highlights changes measured during the study period for large groups of patients, providing context but not individual predictions.


Research on Fixed-Dose Combination Strategy

Studies evaluated the use of a fixed-dose combination versus two separate pills, focusing on outcomes reflecting daily functioning and therapy adherence. Studies explored the use of retrospective claims database analyses to observe patient patterns over periods of up to a year or more. Data show patterns related to patient adherence, and studies evaluated whether the fixed-dose formulation was associated with specific measures of persistence compared to regimens requiring the use of two separate tablets.


What is Still Uncertain in the Research Landscape

The evidence base for Co-Mepril still contains specific gaps and uncertainties noted by regulatory bodies. Comparative evidence is lacking for long-term clinical outcomes (such as cardiovascular events) in studies that directly randomized patients to receive the fixed-dose combination versus those who took the exact same doses of the two components as two separate pills. The safety and efficacy of this particular fixed-dose combination are not fully established in the pediatric population (children and adolescents), meaning there is limited information to inform its use for this age group.

Frequently Asked Questions (FAQ)

Common questions about Co-Mepril (FAQ)

Q: Why is Co-Mepril used for purposes beyond just high blood pressure?

Official information states that the ACE inhibitor component of Co-Mepril is also approved for treating conditions beyond hypertension. This includes heart failure and asymptomatic left ventricular dysfunction. These are serious cardiovascular conditions for which the ACE inhibitor component has received regulatory approval.


Q: Is there a preferred time of day to take Co-Mepril (morning vs. evening)?

The medication is typically prescribed to be taken at the same time each day to maintain consistent blood pressure control. Due to the diuretic component, taking the dose in the morning is generally preferred. This practice is suggested to help reduce the possibility of sleep disruption caused by frequent nighttime urination.


Q: What kind of monitoring (e.g., blood tests) is generally required when taking Co-Mepril?

Regulatory information indicates that regular monitoring by a healthcare professional is generally required to check for proper function. This often involves blood and urine tests to check kidney function and look for potential electrolyte imbalances, such as changes in potassium or sodium levels.


Q: Is it necessary to avoid alcohol completely while undergoing treatment with Co-Mepril?

Regulatory documents describe that alcohol may increase the blood pressure-lowering (hypotensive) effects of the medication. This increase in effect can potentially lead to lightheadedness or dizziness. Patients should discuss their specific use of alcohol with their prescriber.


Q: Can Co-Mepril be used by children, or is it only for adult patients?

Co-Mepril is not recommended for use in the pediatric population, which includes patients under 18 years of age. This is because the safety and efficacy of the combination drug have not been officially established in this age group.


Q: What are the official guidelines regarding use of Co-Mepril in elderly patients?

Official information advises caution when the medication is used in elderly patients. Due to potential age-related changes in organ function, these patients may be more sensitive to the effects of the medication. This sensitivity is a factor that may be considered by a healthcare professional when determining the appropriate starting dose.


Q: Is Co-Mepril considered a cure for my condition, or is it a long-term management tool?

Official regulatory documents state that Co-Mepril is intended to control high blood pressure and other approved conditions; it is not a cure. The medication is a long-term management tool that must be taken continuously as prescribed to maintain blood pressure control.


Q: What are the most important general benefits patients can expect from taking Co-Mepril?

The primary, long-term benefit of taking this medication is the effective lowering of chronic high blood pressure. By achieving this control, the medication helps to significantly reduce the patient's long-term risk of serious cardiovascular events, such as stroke and heart attack.


Q: Is Co-Mepril typically prescribed as a standalone drug or as part of a combination therapy?

Co-Mepril is a fixed-dose combination of two different medicines: an ACE inhibitor and a diuretic. It is not approved for use as an initial therapy. It is generally reserved for patients whose blood pressure is not adequately controlled by treatment with a single drug (monotherapy).


Q: Does the mechanism of Co-Mepril involve water retention or salt balance?

Yes, the mechanism involves managing fluid and electrolyte levels. The diuretic component works specifically by causing the kidneys to remove unneeded water and salt from the body. This action leads to a reduction in overall fluid volume, which helps to lower blood pressure.


Q: Is Co-Mepril known to affect the heart rate or only blood vessel tension?

The primary mechanism of the components focuses on relaxing blood vessel tension and managing fluid volume. However, official safety information documents that a serious side effect, such as low potassium levels, can potentially cause changes in heart rhythm, including a fast or irregular heartbeat.


Q: Do lifestyle changes, like diet and exercise, still matter when taking Co-Mepril?

Yes. Official regulatory and clinical guidance emphasizes that medication works best as part of a comprehensive management plan. This plan includes important non-pharmacological interventions such as following a healthy, reduced-sodium diet and engaging in regular physical activity.


Q: Why does Co-Mepril sometimes cause a cough, and what is the reason for this?

Official documentation states the cough is presumably caused by the ACE inhibitor component blocking an enzyme. This blockage can lead to the accumulation of natural substances like bradykinin, which may irritate the airways and trigger the cough reflex.


Q: Are there any side effects of Co-Mepril that might be a sign of a more serious problem?

Yes, official safety information highlights signs of serious reactions for which patients are advised to seek medical attention. These include sudden swelling of the face, tongue, or throat (angioedema), signs of kidney injury (like a change in urine output), or signs of severe electrolyte problems.


Q: Does taking Co-Mepril cause any gastrointestinal side effects like nausea or stomach upset?

Yes, documented gastrointestinal side effects are associated with this medication. These commonly include general upset stomach, as well as dry mouth, constipation, and dyspepsia (indigestion).


Q: Can Co-Mepril affect sleep patterns or cause insomnia?

Due to the diuretic component, the medicine can cause increased urination. For this reason, official guidance recommends that the dose is not taken too close to bedtime to prevent frequent urination from interrupting sleep patterns.


Q: Is there a restriction on taking Co-Mepril with certain herbal supplements?

Official guidance advises caution regarding the use of over-the-counter products, including some natural products or aids, that may potentially interact with blood pressure. The use of all supplements should be discussed with a healthcare professional.


Q: What is meant by the 'risk-reduction' claims often associated with Co-Mepril?

The risk-reduction claims refer to the medication's ability to reduce a patient's long-term risk of major cardiovascular events. Studies indicate that, by effectively managing chronic high blood pressure, the medication is associated with a decreased likelihood of serious outcomes like stroke or myocardial infarction (heart attack).


Q: Why do official sources sometimes recommend taking two different blood pressure drugs together?

Official clinical guidelines often recommend a two-drug combination, such as the components in Co-Mepril. This approach is commonly used for patients with more severe hypertension or for those whose blood pressure remains uncontrolled by a single medicine. The combination addresses the condition through two complementary pathways.

How should Co-Mepril be stored and disposed of?

How to Store and Dispose of Co-Mepril?

Co-Mepril must be stored according to official regulatory specifications to maintain its stability and effectiveness. The medication should be kept at controlled room temperature, typically defined as below 25 C (77 F).


Storage Requirements

Condition Requirement
Temperature Store below 25 C (Do not freeze).
Protection Protect from excessive moisture, heat, and light.
Container Keep in the original container, tightly closed.
Safety Keep out of the reach and sight of children and pets.

Disposal

Unused or expired Co-Mepril should be disposed of in accordance with local regulatory requirements for pharmaceutical waste, such as a community drug take-back program. It is prohibited to flush the tablets down the toilet or throw them into household trash unless specifically instructed by local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Mepril found in:

A-Z Index: